Trials / Unknown
UnknownNCT01468493
A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 14 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.
Conditions
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2011-11-09
- Last updated
- 2017-04-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01468493. Inclusion in this directory is not an endorsement.